New Project To Develop Consensus-Based Outcomes For Trials Targeting Rare Skin Condition
An international project that aims to develop a harmonized framework on the minimum aspects that should be measured and reported in clinical trials for the genetic skin disorder, epidermolysis bullosa, has drawn the European Medicines Agency’s attention.
You may also be interested in...
EMA To Explain How Trial Transparency & Data Redaction Can Live Together
The European Medicines Agency is working to align the redaction and data anonymization principles underpinning two EU clinical trial transparency initiatives to ensure consistency in disclosure requirements.
ICH Consults On Modernized GCP Principles To Make Clinical Trials More Efficient
The International Council for Harmonisation has issued updated Good Clinical Practice principles to accommodate new clinical trial and data types.
EMA Looks For Efficiencies For Companies Ahead Of Relaunching Clinical Data Transparency Policy
Based on its learnings from proactively publishing clinical trial data on COVID-19 products, the European Medicines Agency is making procedural changes to its clinical data publication policy that is set to resume after being temporarily suspended in 2018.